No Data
No Data
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma
AstraZeneca Hits 4-week High
AstraZeneca (AZN.US) BTK inhibitor new indication approved by the EU for the treatment of mantle cell lymphoma.
AstraZeneca (AZN.US) announced that acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are not suitable for autologous stem cell transplantation.
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag